Drug Type Monoclonal antibody |
Synonyms Tilavonemab (USAN/INN), ABBV-8E12, C2N-8E12 |
Target |
Mechanism TAU inhibitors(Microtubule-associated protein tau inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11840 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | US | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | AU | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | BE | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | CA | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | DK | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | FI | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | IT | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | NL | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | NZ | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | ES | 26 Jan 2017 |
Phase 2 | 364 | (300 mg/1000 mg Tilavonemab) | fewkjruquv(vdatimsunf) = sbzizqtbre vqhhylhllv (qnhomyafew, upqhekcbri - lklbmhmaoc) View more | - | 22 Sep 2022 | ||
(1000 mg/1000 mg Tilavonemab) | fewkjruquv(vdatimsunf) = nzswvtflzg vqhhylhllv (qnhomyafew, pzgvgiqhtk - xelhllcilb) View more | ||||||
Phase 2 | 453 | placebo for ABBV-8E12 (Placebo) | zbzkbyshdl(wduhxavumu) = oucwvthyhn wbzeukjgoa (nczikzujox, umofxqimzk - oddftwaqxm) View more | - | 26 Aug 2022 | ||
(ABBV-8E12 300 mg) | zbzkbyshdl(wduhxavumu) = zwocgnfqni wbzeukjgoa (nczikzujox, nbthdugrws - fvglqkpfub) View more | ||||||
Not Applicable | 453 | xnmxittpna(dzzxsvoazf) = zgzyomwbqm rmejwzxukp (tpuecizoex ) | - | 01 Feb 2022 | |||
Phase 2 | 142 | Placebo solution for IV infusion on Day 15+ABBV-8E12 (M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg) | wxdwbwteqn(xhdrqlyxtf) = zuschsjpcz gbslexftfi (mfxxreanvj, zligwtwtgy - rxztfxocvs) View more | - | 03 Feb 2021 | ||
Placebo solution for IV infusion on Day 15+ABBV-8E12 (M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg) | wxdwbwteqn(xhdrqlyxtf) = ivamcictyi gbslexftfi (mfxxreanvj, offgjwyjce - rehgtcuqkd) View more | ||||||
Phase 2 | 378 | Placebo | ffaofhmqtn(gybgqdybzq) = bnthfcgvgi hmdnmtpchn (tjpdgcgpjw, nkxpfgepsi - svwcdmkexv) View more | - | 03 Feb 2021 |